Follicum has filed a clinical trial application to start a clinical Phase I / II a study to both the the BfArM (the Federal Institute for Drugs and Medical Devices in Germany) and to the Research Ethics Committee. Follicum’s intention is to initiate the study at year-end 2015/early 2016, provided that the application is accepted. […]
In March 2015 Follicum announced that the so called ”Research and Grow”- program which was financed by VINNOVA* could be finalized earlier than planned due to the promising outcome of the program. The company has now received the final results from the program, which come from the specific tissue analysis on human skin from the […]
Follicum has received a preliminary approval – a so called “Intention to Grant” – by the European Patent Office (EPO) regarding the company’s patent application for stimulation of hair growth. To read the full press release (in Swedish) please click here. For more information about Follicum’s research results, please contact: Jan Alenfall, CEO Tel +46 (0)46 19 21 […]
The German research group which has generated important parts of Follicum’s research data on human skin will present their results both as a poster and in an oral presentation at the World Congress for Hair Research. The congress takes place in Miami in Florida, USA, on 18-21 November 2015. To read the full press release […]
As previously communicated, Follicum’s intention is to start a clinical phase I/IIa study around year-end 2015/early 2016. We can now announce that a cooperation with the Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin, Germany, has been initiated regarding our planned clinical phase I/IIa study. Follicum’s intention is to submit an application […]
Follicum announced in March 2015 that they had started two larger toxicity studies to add information to the two short time toxicity studies and continue development. The short time studies were finalized in February 2015, and showed no adverse effects. The two larger toxicity studies have now been finished according to plan, showing very promising […]
Follicum announce today that the synthesis of the peptide has been completed. The peptide is the active ingredient of the product planned to be used in the clinical Phase I/IIa study. Production of product for the clinical Phase I/IIa study Follicum announced in early June that the company had signed an agreement with the peptide […]
Follicum’s half-year report 2015 (1 January to 30 June) is now published. Click here to open the report (in Swedish).
Follicum can today announce that an agreement has been signed with PolyPeptide Group and Recipharm AB prior to the clinical study, which is expected to start around the turn of the year 2015/2016. Read more here.